Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Transcutaneous Auricular Vagus Nerve Stimulation Added to Physiotherapy for Adhesive Capsulitis (taVNS-AC)

14 de julio de 2026 actualizado por: Muhsin Doran

Effect of Transcutaneous Auricular Vagus Nerve Stimulation Added to Standard Physiotherapy on Pain, Function, and Quality of Life in Patients With Shoulder Adhesive Capsulitis: A Randomized Controlled Trial

This randomized, sham-controlled study will evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS), when added to standard physiotherapy, improves pain, shoulder function, range of motion, and quality of life in adults with adhesive capsulitis.

A total of 40 participants aged 18 to 65 years will be randomly assigned to one of two groups. Both groups will receive 15 sessions of standard physiotherapy over 3 weeks. In addition, one group will receive active taVNS for 30 minutes per day, while the other group will receive sham stimulation for the same duration and frequency. Assessments will be performed before treatment and after the 15th treatment session using pain, shoulder disability, quality-of-life, and shoulder range-of-motion measurements.

Descripción general del estudio

Descripción detallada

Adhesive capsulitis is a musculoskeletal condition characterized by shoulder pain and progressive restriction of active and passive range of motion. Although physiotherapy, therapeutic exercise, and manual therapy are commonly used, pain relief and functional recovery may be incomplete in some patients. Therefore, additional non-invasive treatment approaches that may enhance the effects of rehabilitation are clinically relevant.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve. It may influence pain modulation, autonomic nervous system regulation, and inflammatory pathways. Previous studies have reported potential benefits of auricular vagus nerve stimulation in several chronic pain conditions; however, evidence regarding its use in adhesive capsulitis remains limited.

The objective of this study is to determine whether active taVNS added to standard physiotherapy provides greater clinical improvement than sham taVNS added to the same physiotherapy program. The main hypothesis is that participants receiving active taVNS will demonstrate greater reductions in pain and shoulder-related disability after treatment. Secondary objectives are to evaluate changes in shoulder range of motion and health-related quality of life and to assess the tolerability of the intervention.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Istanbul
      • Istanbul, Istanbul, Turquía (Türkiye), 34381
        • Reclutamiento
        • Liv hospital Vadistanbul
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Age between 18 and 65 years.
  • Clinical diagnosis of adhesive capsulitis confirmed by physical examination and, when clinically indicated, imaging.
  • Shoulder pain and limitation of shoulder range of motion for at least 3 months.
  • Provision of written informed consent.
  • General health status sufficient to participate in standard physiotherapy and active or sham transcutaneous auricular vagus nerve stimulation.
  • Ability to comply with the planned treatment sessions and outcome assessments.

Exclusion Criteria:

  • Shoulder stiffness secondary to trauma, surgery, infection, or tumor.
  • Rotator cuff tear, advanced glenohumeral osteoarthritis, or inflammatory rheumatic disease.
  • Glucocorticoid injection into the affected shoulder within the previous 3 months.
  • Surgical intervention involving the affected shoulder within the previous 6 months.
  • Active infection or skin lesion in the shoulder region.
  • Cervical radiculopathy, brachial plexopathy, stroke, or another neurological disorder affecting the upper extremity.
  • Presence of a cardiac pacemaker or another implanted electronic device.
  • Pregnancy or breastfeeding.
  • Serious systemic disease or cognitive impairment that may prevent compliance with the study protocol.
  • Known intolerance or previous adverse reaction to transcutaneous electrical stimulation.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Standard Physiotherapy Plus Active taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks. Active transcutaneous auricular vagus nerve stimulation is administered for 30 minutes during each treatment session in addition to the physiotherapy program.
Active transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy. Electrical stimulation will be delivered transcutaneously through an auricular electrode to a vagally innervated region of the external ear. The physiotherapist administering the stimulation will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week. The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles. Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations. The same physiotherapy protocol will be administered to both study arms.
Comparador falso: Standard Physiotherapy Plus Sham taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks. In addition, sham transcutaneous auricular vagus nerve stimulation is administered for 30 minutes with the same frequency and treatment schedule as the active stimulation.
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week. The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles. Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations. The same physiotherapy protocol will be administered to both study arms.
Sham transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy. The sham procedure will follow the same session frequency and duration as the active intervention but will be applied according to a prespecified sham protocol that is not expected to produce therapeutic vagal stimulation. The physiotherapist administering the intervention will be aware of group allocation, while participants and the outcomes assessor will remain blinded.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Shoulder Pain and Disability Index (SPADI) Total Score
Periodo de tiempo: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
The Shoulder Pain and Disability Index (SPADI) is a 13-item patient-reported questionnaire consisting of a 5-item pain subscale and an 8-item disability subscale. The total score ranges from 0 to 100, with higher scores indicating greater shoulder pain and disability. The primary outcome will be the change in the SPADI total score from baseline to the assessment performed after completion of the 15th treatment session.
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Shoulder Pain Intensity Assessed With the Visual Analog Scale (VAS)
Periodo de tiempo: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
Shoulder pain intensity will be assessed using a 10-cm Visual Analog Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity. The outcome will be calculated as the change in VAS score from baseline to the assessment performed after completion of the 15th treatment session.
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
Change in Shoulder Flexion Range of Motion
Periodo de tiempo: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
Change in Shoulder Flexion Range of Motion Change in Shoulder Abduction Range of Motion Change in Shoulder Extension Range of Motion Change in Shoulder Internal Rotation Range of Motion Change in Shoulder External Rotation Range of Motion Change in Shoulder Horizontal External Rotation Range of Motion Change in Shoulder Horizontal Abduction Range of Motion Change in Shoulder Horizontal Adduction Range of Motion
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
Change in Health-Related Quality of Life Assessed With the 36-Item Short Form Health Survey (SF-36)
Periodo de tiempo: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The questionnaire evaluates eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored from 0 to 100, with higher scores indicating better health-related quality of life. Changes in domain scores from baseline to the post-treatment assessment will be evaluated.
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Muhsin Doran, Liv hospital Vadistanbul

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de junio de 2026

Finalización primaria (Estimado)

1 de octubre de 2026

Finalización del estudio (Estimado)

1 de octubre de 2026

Fechas de registro del estudio

Enviado por primera vez

14 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de julio de 2026

Publicado por primera vez (Actual)

17 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • LIV-FTR-taVNS-AC-2026-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared. Study findings will be reported only in aggregate form to protect participant confidentiality, and no external IPD-sharing procedure has been established for this study.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir